MonoFIX‐VF, a new mono‐component factor IX concentrate: a single‐centre continuous‐infusion study

Summary.  MonoFIX‐VF, a monocomponent factor IX concentrate, has replaced the use of Prothrombinex‐HT as the treatment of choice for patients with factor IX deficiency in Australia. The haemostatic effect of MonoFIX‐VF, administered by continuous infusion, was assessed in four subjects being treated for 10 bleeding episodes including five surgical procedures. MonoFIX‐VF was found to be a safe and effective treatment for patients with haemophilia B.